Rina S Fox1,2, Sonia Ancoli-Israel1,3,4, Scott C Roesch1,5, Erin L Merz6, Sarah D Mills7, Kristen J Wells1,3,5, Georgia Robins Sadler1,3,4, Vanessa L Malcarne8,9,10,11. 1. San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego State University/University of California, San Diego, San Diego, CA, USA. 2. Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3. Moores Cancer Center, University of California, San Diego, San Diego, CA, USA. 4. University of California, San Diego, San Diego, CA, USA. 5. San Diego State University, San Diego, CA, USA. 6. California State University, Dominguez Hills, Carson, CA, USA. 7. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 8. San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego State University/University of California, San Diego, San Diego, CA, USA. vmalcarne@sdsu.edu. 9. Moores Cancer Center, University of California, San Diego, San Diego, CA, USA. vmalcarne@sdsu.edu. 10. University of California, San Diego, San Diego, CA, USA. vmalcarne@sdsu.edu. 11. San Diego State University, San Diego, CA, USA. vmalcarne@sdsu.edu.
Abstract
PURPOSE: Sleep disturbance and cancer-related fatigue (CRF) are among the most commonly reported symptoms associated with breast cancer and its treatment. This study identified symptom cluster groups of breast cancer patients based on multidimensional assessment of sleep disturbance and CRF prior to and during chemotherapy. METHODS: Participants were 152 women with stage I-IIIA breast cancer. Data were collected before chemotherapy (T1) and during the final week of the fourth chemotherapy cycle (T2). Latent profile analysis was used to derive groups of patients at each timepoint who scored similarly on percent of the day/night asleep per actigraphy, the Pittsburgh Sleep Quality Index global score, and the five subscales of the Multidimensional Fatigue Symptom Inventory-Short Form. Bivariate logistic regression evaluated if sociodemographic/medical characteristics at T1 were associated with group membership at each timepoint. RESULTS: Three groups (Fatigued with sleep complaints, Average, Minimal symptoms) were identified at T1, and five groups (Severely fatigued with poor sleep, Emotionally fatigued with average sleep, Physically fatigued with average sleep, Average, Minimal symptoms) at T2. The majority of individuals in a group characterized by more severe symptoms at T1 were also in a more severe symptom group at T2. Sociodemographic/medical variables at T1 were significantly associated with group membership at T1 and T2. CONCLUSIONS: This study identified groups of breast cancer patients with differentially severe sleep disturbance and CRF symptom profiles prior to and during chemotherapy. Identifying groups with different symptom management needs and distinguishing groups by baseline sociodemographic/medical variables can identify patients at risk for greater symptom burden.
PURPOSE:Sleep disturbance and cancer-related fatigue (CRF) are among the most commonly reported symptoms associated with breast cancer and its treatment. This study identified symptom cluster groups of breast cancerpatients based on multidimensional assessment of sleep disturbance and CRF prior to and during chemotherapy. METHODS:Participants were 152 women with stage I-IIIA breast cancer. Data were collected before chemotherapy (T1) and during the final week of the fourth chemotherapy cycle (T2). Latent profile analysis was used to derive groups of patients at each timepoint who scored similarly on percent of the day/night asleep per actigraphy, the Pittsburgh Sleep Quality Index global score, and the five subscales of the Multidimensional Fatigue Symptom Inventory-Short Form. Bivariate logistic regression evaluated if sociodemographic/medical characteristics at T1 were associated with group membership at each timepoint. RESULTS: Three groups (Fatigued with sleep complaints, Average, Minimal symptoms) were identified at T1, and five groups (Severely fatigued with poor sleep, Emotionally fatigued with average sleep, Physically fatigued with average sleep, Average, Minimal symptoms) at T2. The majority of individuals in a group characterized by more severe symptoms at T1 were also in a more severe symptom group at T2. Sociodemographic/medical variables at T1 were significantly associated with group membership at T1 and T2. CONCLUSIONS: This study identified groups of breast cancerpatients with differentially severe sleep disturbance and CRF symptom profiles prior to and during chemotherapy. Identifying groups with different symptom management needs and distinguishing groups by baseline sociodemographic/medical variables can identify patients at risk for greater symptom burden.
Authors: Sonia Ancoli-Israel; Jennifer L Martin; Terri Blackwell; Luis Buenaver; Lianqi Liu; Lisa J Meltzer; Avi Sadeh; Adam P Spira; Daniel J Taylor Journal: Behav Sleep Med Date: 2015 Impact factor: 2.964
Authors: Christine Miaskowski; Bruce A Cooper; Michelle Melisko; Lee-May Chen; Judy Mastick; Claudia West; Steven M Paul; Laura B Dunn; Brian L Schmidt; Marilyn Hammer; Frances Cartwright; Fay Wright; Dale J Langford; Kathryn Lee; Bradley E Aouizerat Journal: Cancer Date: 2014-05-02 Impact factor: 6.860
Authors: Christine Miaskowski; Bruce A Cooper; Steven M Paul; Marylin Dodd; Kathryn Lee; Bradley E Aouizerat; Claudia West; Maria Cho; Alice Bank Journal: Oncol Nurs Forum Date: 2006-09-01 Impact factor: 2.172
Authors: Sonia Ancoli-Israel; Roger Cole; Cathy Alessi; Mark Chambers; William Moorcroft; Charles P Pollak Journal: Sleep Date: 2003-05-01 Impact factor: 5.849
Authors: Melissa S Y Thong; Floortje Mols; Lonneke V van de Poll-Franse; Mirjam A G Sprangers; Carin C D van der Rijt; Andrea M Barsevick; Hans Knoop; Olga Husson Journal: J Cancer Surviv Date: 2017-09-09 Impact factor: 4.442
Authors: Sy-Huey Doong; Anand Dhruva; Laura B Dunn; Claudia West; Steven M Paul; Bruce A Cooper; Charles Elboim; Gary Abrams; John D Merriman; Dale J Langford; Heather Leutwyler; Christina Baggott; Kord Kober; Bradley E Aouizerat; Christine Miaskowski Journal: Biol Res Nurs Date: 2014-10-10 Impact factor: 2.522
Authors: Ivan H C Wu; Diwakar D Balachandran; Saadia A Faiz; Lara Bashoura; Carmen P Escalante; Ellen F Manzullo Journal: J Pain Symptom Manage Date: 2021-08-01 Impact factor: 3.612
Authors: Susan Grayson; Susan Sereika; Caroline Harpel; Emilia Diego; Jennifer G Steiman; Priscilla F McAuliffe; Susan Wesmiller Journal: Support Care Cancer Date: 2021-07-10 Impact factor: 3.603
Authors: Rina S Fox; Sharon H Baik; Heather McGinty; Sofia F Garcia; Kathryn J Reid; Katrin Bovbjerg; Precilla Fajardo; Lisa M Wu; Shohreh Shahabi; Jason C Ong; Phyllis C Zee; Frank J Penedo Journal: Int J Behav Med Date: 2021-02